English
Hikal Q4 Results
- BSE: 524735
- NSE: HIKAL
- ISIN: INE475B01022
- Sector: Biotechnology & Drugs
BSE
231.65
-8.55 (-3.56%)
-8.55 (-3.56%)Volume14.11 K
Updated: Fri 14 Nov, 2025 | 15:29:48
NSE
230.78-9.59 (-3.99%)
-9.59 (-3.99%)Volume4.63 L
Updated: Fri 14 Nov, 2025 | 15:52:21
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Hikal Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 466.70 | 408.80 | 14.16% | 451.98 | 3.26% |
| Depreciation/ Amortization | 37.70 | 33.20 | 13.55% | 32.34 | 16.57% |
| Operating Income | 85.70 | 38.90 | 120.31% | 62.12 | 37.96% |
| Net Income | 50.20 | 17.20 | 191.86% | 33.97 | 47.77% |
| Other Operating Expenses Total | 133.40 | 100.20 | 33.13% | 121.61 | 9.69% |
| Net Income Before Taxes | 68.30 | 23.80 | 186.97% | 47.33 | 44.32% |
| Total Revenue | 552.40 | 447.70 | 23.39% | 514.10 | 7.45% |
| Selling/ General/ Admin Expenses Total | 63.40 | 64.50 | -1.71% | 63.78 | -0.59% |
| Diluted Normalized EPS | 4.08 | 1.39 | 193.64% | 2.75 | 48.19% |